electroCore, Inc. (Nasdaq: ECOR), shares were up 17.52% to $3.22 in the extended-hours session last night. Furthermore, the stock gained 69.14% in the past one month, 74.52% in three months, and 70.19% in six months. Measured by its price volatility, ECOR volatility last week was 20.56%, whereas volatility over the past month was 10.0%.
What they do…
electroCore, Inc. (Nasdaq: ECOR)uses advanced non-invasive vagus nerve stimulation technology to improve patient outcomes in neurology.
January 21, 2021,electroCore, Inc. (Nasdaq: ECOR) has announced that Health Improvement Scotland has published a document that outlines the use of gammaCore for cluster headache. SHTG’s publication is based on supporting evidence from the U.K. National Institute of Health and Care Excellence indicated that by using gammaCore in conjunction with standard treatment for cluster headache, quality of life increases for people living with this condition, and electroCore offers free evaluations for all patients, resulting in a reduction in acute rescue medication use and £450 in the first year of treatment.
NHS Scotland has adopted the SHTG recommendation to distribute the SHTG adaptation across NHS Scotland health boards and disseminate its use to treat cluster headaches for a three-month trial.
According to the prices targeted by Wall Street analysts for ECOR, six analysts have provided forecasts with a consensus price target of $3.50. If the stock’s price has a downside, analysts have set its value between $5.00 and $3.00 over the next year. Interestingly, analysts expect electroCore Inc.’s stock to finish the following year with a 2.00 rating. Consequently, if the stock’s price were to rise for the next 12 months, it would gain 8.67% in value. Nevertheless, the stock would hit the forecast high price target of $4.25, while the stock’s mean target price is $3.75.